Absolute oral bioavailability and pharmacokinetics of canagliflozin: A microdose study in healthy participants

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Clinical pharmacology in drug development

• Publication date

  2015-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/cpdd.162PMID 27136910
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• In vitro and physiologically‐based pharmacokinetic based assessment of drug–drug interaction potential of canagliflozin

  2017cited by this paper
• Effect of food on the pharmacokinetics of canagliflozin, a sodium glucose co‐transporter 2 inhibitor, and assessment of dose proportionality in healthy participants

  2015cited by this paper
• Metabolism and Excretion of Canagliflozin in Mice, Rats, Dogs, and Humans

  2014cited by this paper
• Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants

  2014cited by this paper
• Simultaneous oral therapeutic and intravenous ¹⁴C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin.

  2013cited by this paper
• Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion

  2013cited by this paper
• Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Sodium Glucose Co‐Transporter 2 Inhibitor, in Subjects With Type 2 Diabetes Mellitus

  2013cited by this paper
• Canagliflozin, a new sodium-glucose cotransporter 2 inhibitor, in the treatment of diabetes.

  2013cited by this paper
• Absolute Oral Bioavailability and Metabolic Turnover of β-Sitosterol in Healthy Subjects

  2012cited by this paper
• Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin

  2012cited by this paper
• Recent advances in biomedical applications of accelerator mass spectrometry

  2009cited by this paper
• Use of an intravenous microdose of 14C-labeled drug and accelerator mass spectrometry to measure absolute oral bioavailability in dogs; cross-comparison of assay methods by accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry.

  2009cited by this paper
• Biomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokinetics

  2008cited by this paper
• Workshop/conference report—Quantitative bioanalytical methods validation and implementation: Best practices for chromatographic and ligand binding assays

  2007cited by this paper
• Novel use of accelerator mass spectrometry for the quantification of low levels of systemic therapeutic recombinant protein.

  2006cited by this paper
• Guidance for Industry, Investigators, and Reviewers: Exploratory IND Studies

  2006cited by this paper
• The Application of Accelerator Mass Spectrometry to Absolute Bioavailability Studies in Humans: Simultaneous Administration of an Intravenous Microdose of 14C‐Nelfinavir Mesylate Solution and Oral Nelfinavir to Healthy Volunteers

  2005cited by this paper
• Quantitating isotopic molecular labels with accelerator mass spectrometry.

  2005cited by this paper
• Bioanalytical Method Validation—A Revisit with a Decade of Progress

  2000cited by this paper
• Absolute bioavailability in man of N‐acetylprocainamide determined by a novel stable isotope method

  1975cited by this paper

• Exploring the Role of SGLT2 Inhibitors in Cancer: Mechanisms of Action and Therapeutic Opportunities

  2025influential citation
• Research on Enhancing the Solubility and Bioavailability of Canagliflozin Using Spray Drying Techniques with a Quality-by-Design Approach

  2025cites this paper
• Unraveling PPARβ/δ nuclear receptor agonists via a drug-repurposing approach: HTVS-based ligand identification, molecular dynamics, pharmacokinetics, and in vitro anti-steatotic validation

  2025cites this paper
• Clinical pharmacokinetics on canagliflozin: a systematic review of in-vitro and in-vivo studies

  2025influential citation
• Pharmacokinetics and Alterations in Glucose and Insulin Levels After a Single Dose of Canagliflozin in Healthy Icelandic Horses

  2024influential citation
• SGLT-2 Inhibitors’ and GLP-1 Receptor Agonists’ Influence on Neuronal and Glial Damage in Experimental Stroke

  2024cites this paper
• Clotrimazole Identified as a Selective UGT2B4 Inhibitor Using Canagliflozin-2′-O-Glucuronide Formation as a Selective UGT2B4 Probe Reaction

  2024cites this paper
• Absolute and Relative Bioavailability of Oral Solid Dosage Formulations of Deucravacitinib in Humans

  2023cites this paper
• Comparison of SGLT1, SGLT2, and Dual Inhibitor Biological Activity in Treating Type 2 Diabetes Mellitus

  2023cites this paper
• Canagliflozin, an Inhibitor of the Na+-Coupled D-Glucose Cotransporter, SGLT2, Inhibits Astrocyte Swelling and Brain Swelling in Cerebral Ischemia

  2023cites this paper
• Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α

  2023influential citation
• Impact of SGLT2 inhibitors on the kidney in people with type 2 diabetes and severely increased albuminuria

  2022cites this paper
• Canagliflozin: metabolic, cardiovascular and renal protection.

  2021cites this paper
• PBPK Modeling as a Tool for Predicting and Understanding Intestinal Metabolism of Uridine 5′-Diphospho-glucuronosyltransferase Substrates

  2021cites this paper
• Bioequivalence of two esomeprazole magnesium enteric-coated formulations in healthy Chinese subjects

  2020cites this paper
• Why Collecting Pharmacokinetic Information After Intravenous Drug Administration Is Important

  2020cites this paper
• Sodium-glucose cotransporter-2 inhibitors: updated evidence on their efficacy and safety in patients with type-2 diabetes

  2020cites this paper
• Effects of canagliflozin on growth and metabolic reprograming in hepatocellular carcinoma cells: Multi-omics analysis of metabolomics and absolute quantification proteomics (iMPAQT)

  2020cites this paper
• Development and Validation of Reverse Phase High Performance Liquid Chromatography Method for the Estimation of Canagliflozin in Bulk and its Pharmaceutical Formulation

  2020cites this paper
• Glycaemic and weight-loss outcomes of graded doses of canagliflozin in type 2 diabetes — a real-world study

  2020cites this paper
• Acute canagliflozin treatment protects against in vivo myocardial ischemia–reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation

  2019cites this paper
• Characterization of forced degradation products of canagliflozine by liquid chromatography/quadrupole time-of-flight tandem mass spectrometry and in silico toxicity predictions.

  2018cites this paper
• An Accelerator Mass Spectrometry‐Enabled Microtracer Study to Evaluate the First‐Pass Effect on the Absorption of YH4808

  2017cites this paper
• In vitro and physiologically‐based pharmacokinetic based assessment of drug–drug interaction potential of canagliflozin

  2017cites this paper
• Spotlight on Canagliflozin 300: review of its efficacy and an indirect comparison to other SGLT-2 inhibitors and long-acting GLP-1 receptor agonists

  2017cites this paper
• Canagliflozin: A Review in Type 2 Diabetes

  2017cites this paper
• A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus

  2017cites this paper
• Single-dose Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Selective Inhibitor of Sodium Glucose Cotransporter 2, in Healthy Indian Participants.

  2016cites this paper
• RP-HPLC Method Development and Validation forthe Determination of Canagliflozin in Human Plasma

  2016cites this paper
• The synthesis of [(14) C]AZD5122. Incorporation of an IV (14) C-microtracer dose into a first in human study to determine the absolute oral bioavailability of AZD5122.

  2016cites this paper
• Approaches to intravenous clinical pharmacokinetics: Recent developments with isotopic microtracers

  2016cites this paper
• Canagliflozin: a sodium glucose co‐transporter 2 inhibitor for the treatment of type 2 diabetes mellitus

  2015cites this paper
• Clinical Pharmacokinetic, Pharmacodynamic, and Drug–Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor

  2015influential citation
• Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.

  2015cites this paper